FDA Approves Moderna's mRNA Flu Vaccine After Initial Pushback The FDA's approval of Moderna's mFLUSIVA, a seasonal flu vaccine using mRNA technology, has sparked a mix of excitement and skepticism.
While some hail it as a breakthrough in immunology, others are questioning the implications of this new approach to vaccine development. A Long Time Coming?
The FDA's review process for mFLUSIVA was not without controversy.